Researchers Identify Novel Allosteric Inhibitors of Citrate Transporter NaCT for Metabolic and Neurological Disease
Scientists discovered small molecule inhibitors targeting an allosteric binding site on the NaCT protein, a transporter implicated in metabolic and neurological diseases including a rare form of epilepsy. The study screened 3.5 million compounds and identified six lead compounds with improved potency through virtual screening and experimental validation. This approach offers a chemically distinct alternative to existing substrate-competitive inhibitors and could enable development of new therapeutic options for SLC13A5-related epilepsy and other NaCT-associated conditions.
Researchers used computational and experimental methods to identify novel inhibitors of NaCT (SLC13A5), a sodium-dependent citrate transporter that regulates citrate homeostasis and is implicated in metabolic and neurological diseases, particularly SLC13A5 Epilepsy—a rare genetic disorder characterized by severe seizures and neurodevelopmental delays. The team conducted a virtual screen of 3.5 million compounds from the ZINC20 database targeting a previously uncharacterized allosteric binding site at the protein's dimer interface, then validated 54 candidates using cell-based assays. Initial screening identified three weak inhibitors, and subsequent structural optimization of related analogs yielded six compounds with improved potency (IC₅₀ values of 12.78 and 15.49 μM). The researchers integrated structural data with deep mutational scanning and comparative homolog analysis to characterize the binding site, identifying key residues such as Phe362 critical for ligand modulation. These findings establish a chemically distinct series of NaCT inhibitors that differ from existing substrate-competitive approaches, providing a foundation for rational drug development targeting this therapeutic target.
What's missing
The study does not discuss in vitro or in vivo efficacy in disease models, selectivity against related transporters, pharmacokinetic properties, or toxicity profiles of the lead compounds—information typically needed to assess translational potential toward clinical development.
What different sources said
- bioRxivCenter
Targeting an allosteric binding site in the citrate transporter NaCT (SLC13A5)
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.